Excess capacity of the iron regulatory protein system.

Excess capacity of the iron regulatory protein system. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Excess capacity of the iron regulatory protein system. Abstract Text:

Wei Wang,Xiumin Di,Ralph B D'Agostino,Suzy V Torti,Frank M Torti,

Iron regulatory proteins (IRP1 and IRP2) are master regulators of cellular iron metabolism. IRPs bind to iron-responsive elements (IREs) present in the untranslated regions of mRNAs encoding proteins of iron storage, uptake, transport, and export. Because simultaneous knockout of IRP1 and IRP2 is embryonically lethal, it has not been possible to use dual knockouts to explore the consequences of loss of both IRP1 and IRP2 in mammalian cells. In this report, we describe the use of small interfering RNA to assess the relative contributions of IRP1 and IRP2 in epithelial cells. Stable cell lines were created in which either IRP1, IRP2, or both were knocked down. Knockdown of IRP1 decreased IRE binding activity but did not affect ferritin H and transferrin receptor 1 (TfR1) expression, whereas knockdown of IRP2 marginally affected IRE binding activity but caused an increase in ferritin H and a decrease in TfR1. Knockdown of both IRPs resulted in a greater reduction of IRE binding activity and more severe perturbation of ferritin H and TfR1 expression compared with single IRP knockdown. Even though the knockdown of IRP-1, IRP-2, or both was efficient, resulting in nondetectable protein and under 5% of wild type levels of mRNA, all stable knockdowns retained an ability to modulate ferritin H and TfR1 appropriately in response to iron challenge. However, further knockdown of IRPs accomplished by transient transfection of small interfering RNA in stable knockdown cells completely abolished the response of ferritin H and TfR1 to iron challenge, demonstrating an extensive excess capacity of the IRP system.

Excess capacity of the iron regulatory protein system. Publishing Authors By Initials

W Wang,X Di,RB D'Agostino,SV Torti,FM Torti,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Excess capacity of the iron regulatory protein system. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: The Journal of biological chemistry

VOLUME: 282

Page Numbers: 24650-9

Journal Abbreviation: J. Biol. Chem.

ISSN: 0021-9258

DAY: 28

MONTH: 06

YEAR: 2007

Excess capacity of the iron regulatory protein system. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 2985121

Excess capacity of the iron regulatory protein system. Keywords Mesh Terms:

KEYWORDS: Reverse Transcriptase Polymerase Chain R

MESH TERMS: metabolism

Chemical & Substance for Abstract: Excess capacity of the iron regulatory protein system. Information

Substance Name: Iron Regulatory Protein 2

Registry Number: EC 4.2.1.3

Grant and Affiliation Information for Excess capacity of the iron regulatory protein system.

AFFILIATION: Department of Cancer Biology, Public Health Sciences, Wake Forest University Health Sciences, Winston-Salem, North Carolina 27157, USA.

Country: United States

AGENCY: United States NIDDK

GRANT: R37 DK42412

ACRONYM: DK

MEDLINETA: J Biol Chem

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Excess capacity of the iron regulatory protein system Related Publications

• A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma.
• Cleavage of high-molecular-weight kininogen by elastase and tryptase is inhibited by ferritin.
• Contribution of protease-activated receptors 1 and 4 and glycoprotein Ib-IX-V in the G(i)-independent activation of platelet Rap1B by thrombin.
• Curcumin: From ancient medicine to current clinical trials.
• Dideoxynucleoside HIV reverse transcriptase inhibitors and drug-related hepatotoxicity: a case report.
• Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV.
• Excess capacity of the iron regulatory protein system.
• Managing hot flashes in men being treated for prostate cancer.
• Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors.
• Prostatic cancer chemotherapy.
• Response criteria in urologic malignancies.
• Risk of Early Virological Failure of Once-Daily Tenofovir-Emtricitabine plus Twice-Daily Nevirapine in Antiretroviral Therapy-Naive HIV-Infected Patients.
• Targeting of the small GTPase Rap2b, but not Rap1b, to lipid rafts is promoted by palmitoylation at Cys176 and Cys177 and is required for efficient protein activation in human platelets.
• The chemotherapy of bladder carcinoma: systemic therapy.
• Treatment of metastatic renal cell carcinoma.
• Updated prevalence of genotypic resistance among HIV-1 positive patients naïve to antiretroviral therapy: a single center analysis.